Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Diarrhea and colitis are among the most commonly encountered immune-mediated adverse events among patients receiving antiprogrammed cell death protein/ligand-1 (PD-1/L1) as well as anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies. With growing indications and widespread use of immune checkpoint inhibitors, it is imperative to summarize the current body of evidence concerning the incidence, pathogenesis, risk factors, diagnostic challenges, and treatment options currently available for the management of immune-mediated diarrhea and colitis. Additionally, with emerging evidence analyzing the resumption of immune checkpoint inhibitors, it is pivotal to summarize our current understanding and future challenges. RECENT FINDINGS: Immune-mediated diarrhea and colitis can potentially be a viable surrogate marker for improved survival as it is validated further in large-scale studies. Early endoscopic evaluation can aid in the identification of patients at risk of developing steroid refractory immune-mediated colitis, and hence can be chosen to receive early add-on therapy with infliximab, vedolizumab or fecal microbiota transplantation, an emerging treatment option for immune-mediated diarrhea and colitis. Resuming immune checkpoint inhibitors carries a manageable risk of recurrent diarrhea and colitis, with most cases being mild and effectively managed with immunosuppressive therapy. SUMMARY: As our understanding of immune-mediated diarrhea and colitis grows, it is likely that this clinicopathologic entity will represent more than just an adverse event. With a growing number of treatment options, the management algorithms for immune-mediated diarrhea/colitis are likely to evolve in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Particularly for the gastrointestinal irAEs, which represent the most common toxicity associated with ICB (Abu-Sbeih et al., 2020), microbiome modulation may be an effective strategy to alleviate symptoms.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Abu-Sbeih et al., 2020
In the citing paper
“Particularly for the gastrointestinal irAEs, which represent the most common toxicity associated with ICB (Abu-Sbeih et al., 2020), microbiome modulation may be an effective strategy to alleviate symptoms.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Abu-Sbeih et al., 2020
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · cited 1×
“a major proportion of irAEs leading to a mortality with anti-CTLA-4 ICI use [15].”
BackgroundAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · cited 1×
“It is important to identify severe grade IMDC early as it has been reported to lead to colonic perforation, particularly when there is a delay in diagnosis [16,17].”
BackgroundKhoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Cited by
Zou, F., Wang, X., Oliva, I. C. G., McQuade, J. L., Wang, J. R., Zhang, H. C., Thompson, J. A., Thomas, A. S., & Wang, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002058 · Cited by 81
The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients
Moschen, A. R., Sammy, Y., Marjenberg, Z. R., Heptinstall, A. B., Pooley, N., & Marczewska, A. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01267-3 · Cited by 42
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Zou, F., Abu‐Sbeih, H., Ma, W., Peng, Y., Qiao, W., Wang, J., Shah, A. Y., Oliva, I. C. G., Piha-Paul, S. A., Thompson, J. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7647 · Cited by 31
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
Terrin, M., Migliorisi, G., Buono, A. D., Gabbiadini, R., Mastrorocco, E., Quadarella, A., Repici, A., Santoro, A., & Armuzzi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411504 · Cited by 34
The significance of histological activity measurements in immune checkpoint inhibitor colitis
Pai, R. K., Pai, R. K., Brown, I., Choi, W., Schaeffer, D. F., Farnell, D., Kumarasinghe, P. M., Gunawardena, D., Kim, B. H., Friedman, M., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16142 · Cited by 24
Metadata
- Authors
- Abu-Sbeih, H., Ali, F. S., & Wang, Y.
- Affiliations
- Saint Joseph Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Ali, Faisal S.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2020-01
- Volume
- 36
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2980408506
- Cited by
- 30
- References
- 39
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 4 · 2020: 4
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- immune checkpoint inhibitors, immune-related colitis, PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, immune-related adverse events, steroid-refractory colitis, infliximab, vedolizumab, fecal microbiota transplantation, immunosuppressive therapy, endoscopy
- MeSH terms
- Immune Checkpoint Inhibitors, Colitis, Diarrhea, Humans, Neoplasms, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. https://app.cochat.ai/papers/10.1097/mog.0000000000000593
- The paper
- Abu-Sbeih, H., Ali, F. S., & Wang, Y. (2020). Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.